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Abstract: Pregabalin is one of the latest antiepileptic drugs introduced for the treatment 
of partial epilepsy. Its efﬁ  cacy and safety as adjunctive therapy in refractory partial epilepsy 
have been established in four double-blind placebo-controlled trials (n = 1396) and 4 long-term 
open-label studies (n = 1480). In 3 ﬁ  xed-dose trials, the proportion of patients with a 50% 
reduction in seizure frequency across the effective dose-range (150–600 mg/day) ranged between 
14% and 51%, with a clear dose-response relationship. Suppression of seizure activity could 
be demonstrated as early as day 2. The most frequently reported CNS-related adverse events 
included dizziness, somnolence, ataxia and fatigue, were usually mild or moderate, and tended 
to be dose related. In long-term studies, weight gain was reported as an adverse event by 24% 
of patients. When pregabalin dose was individualized to according to response within the 
150 to 600 mg/day dose range, tolerability was considerably improved compared with use of a 
high-dose, ﬁ  xed-dose regimen (600 mg/day) without titration. In long-term studies up to 4 years, 
no evidence of loss efﬁ  cacy was identiﬁ  ed. During the last year on pregabalin, 3.7% of patients 
were seizure-free. Pregabalin appears to be a useful addition to the therapeutic armamentariun 
for the management of refractory partial epilepsy.
Keywords: pregabalin, antiepileptic drugs, adjunctive therapy, partial seizures, efﬁ  cacy, tolerability, 
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Introduction
Pregabalin was granted a license as an antiepileptic drug (AED) for the adjunctive 
treatment of refractory partial seizures in the European Union in 2004 and in the United 
States in 2005. Since then, three other AEDs, namely stiripentol, ruﬁ  namide and lacos-
amide, have received regulatory approval in the European Union. This implies that 
physicians treating epilepsy can now utilize an armamentarium of almost 20 AEDs. 
Since each of these drugs differs from the others, the opportunity of tailoring AED 
choice to the individual characteristics of the patient has never been greater. On the 
other hand, physicians also face complex knowledge challenges, because optimal use 
of these drugs requires a good understanding of their activity against different seizure 
types, pharmacokinetic characteristics, titration and dosing regimens, adverse effects 
proﬁ  le and potential drug-drug interactions (Perucca 2002). The present article will 
review the most relevant pharmacological and clinical properties which are available 
for pregabalin.
Most clinical data discussed in this review are derived from prospective random-
ized controlled trials. These are undoubtedly the most important source of information 
about the value of a drug, since they provide an objective perspective of their efﬁ  cacy, 
tolerability and safety. During the pre-registration development of an AED, however, 
clinical trials are designed primarily to meet the requirements of regulatory authorities, 
eg, to document efﬁ  cacy in terms of superiority over placebo and an acceptable risk to 
beneﬁ  t ratio. Physicians and patients, however, are more concerned about long-term 
clinical utility, and, most importantly, about efﬁ  cacy and tolerability in comparison with 
other AEDs which are available for the same indication(s). In the case of pregabalin, Neuropsychiatric Disease and Treatment 2008:4(6) 1212
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only limited long-term data are available, and trials comparing 
this agent with other AEDs have not yet been completed.
Pharmacological proﬁ  le
Pregabalin displays potent anticonvulsant activity in a variety 
of experimental models of seizures in rodents, including 
seizure induced by maximal electroshock and seizures 
provoked by chemoconvulsants such as pentylenetetrazole, 
bicuculline, and picrotoxin (Ben-Menachem 2004; Warner 
and Figgit 2005; Taylor and Vartanian 1997). Pregabalin is 
also active in animal models of epilepsy, being effective in 
protecting against audiogenic seizures in genetically seizure-
susceptible DBA/2 mice and against kindled seizures in rats. 
The latter model is considered to be predictive of clinical 
efﬁ  cacy against partial-onset seizures. Pregabalin does not 
suppress spontaneous seizures in the Genetic Absence Epi-
lepsy Rat from Strasbourg (GAERS), a model of absence 
epilepsy.
In other preclinical studies, pregabalin has been found 
to be effective in animal models of anxiety and neuropathic 
pain (Shneker et al 2005; Vartanian et al 2006). These 
observations have led to clinical trials and demonstration 
of efﬁ  cacy in patients with generalized anxiety disorder, 
postherpetic neuralgia and painful diabetic peripheral 
neuropathy (Frampton and Scott 2004; Shneker et al 2005; 
Bandelow et al 2007; Blommel and Blommel 2007; Owen 
2007; Tassone et al 2007).
Pregabalin is structurally related to both γ-aminobutyric 
acid (GABA) and gabapentin. However, as for gabapentin, 
the primary mechanism underlying its pharmacological 
action does not appear to involve the GABA system. In 
particular, pregabalin does not bind to GABAA, GABAB 
or benzodiazepine receptors and is neither metabolically 
converted to GABA or to a GABA agonist, nor it has any 
effect on the uptake or degradation of GABA (Errante and 
Petroff 2002; Ben-Menachem 2004). In fact, the primary 
mode of action of pregabalin appears to involve inhibition 
of depolarization-induced calcium inﬂ  ux at P, Q and N-type 
voltage-gated calcium channels, resulting in decreased 
release of excitatory neurotransmitters such as glutamate 
from nerve terminals. At molecular level, this action results 
from pregabalin binding to the α-2-δ subunit of calcium chan-
nels (Ben-Menachem 2004; Warner and Figgit 2005; Fink 
et al 2002; Dooley et al 2002; Li et al 2005 ). Although the 
mechanism of action of pregabalin does not appear to differ 
from that of gabapentin, the afﬁ  nity of pregabalin for the 
α-2-δ modulatory site is much greater than that of gabapentin. 
This explains why pregabalin is 3- to 6-fold more potent than 
gabapentin in animal models of seizures and epilepsy, and 
also in models of anxiety and neuropathic pain.
Clinical pharmacokinetics
Unlike gabapentin, which shows dose-dependent phar-
macokinetics due to decreasing oral bioavailability with 
increasing dosages, pregabalin exhibits dose-independent 
pharmacokinetics (Ben-Menachem 2004; Warner and Figgit 
2005). This implies that, within the effective dose-range, 
plasma pregabalin concentrations are linearly related to the 
prescribed daily dose .
Pregabalin is rapidly and virtually completely absorbed 
from the gastrointestinal tract, with peak plasma concen-
trations being observed after about 1 hour of drug intake 
(Ben-Menachem 2004). The extent of absorption is not 
affected by concomitant intake of food. Like gabapentin, 
pregabalin is absorbed from the upper intestine by an amino 
acid carrier system with afﬁ  nity for large neutral amino acids 
(Jezyk et al 1999), although there seem to be differences 
in regional distribution and sodium dependence between 
the carrier system for pregabalin and the carrier system for 
gabapentin (Piyapolrungroj et al 2001). Most importantly, 
the amino acid carrier responsible for the active uptake of 
pregabalin in the intestine does not become saturated within 
the clinically used dose range. Therefore, the oral bioavail-
ability of pregabalin remains above 90% throughout the 
effective dose range. The same does not apply to gabapentin, 
which has incomplete bioavailability, is absorbed in only a 
limited region of the small intestine, and undergoes saturable 
absorption within the therapeutic dose range, resulting in 
dose-dependent pharmacokinetics, high inter-patient vari-
ability, and potentially ineffective drug exposure (McLean 
1994; Cundy et al 2008).
Pregabalin is not bound to plasma proteins and crosses 
efﬁ  ciently the blood–brain barrier, although with some delay 
compared with its appearance into the bloodstream (Feng 
et al 2001). Pregabalin is negligibly metabolized (2% of 
the dose) and is eliminated primarily in urine in unchanged 
form. The half-life of pregabalin is about 6 hours on average, 
and is independent of dose and duration of administration 
(Ben-Menachem 2004). Animal studies, however, suggest 
that there is a temporal dissociation between plasma prega-
balin levels and anticonvulsant action, and that duration of 
effect may be longer than expected from the half-life of the 
drug in plasma (Feng et al 2001).
There is little information on the inﬂ  uence of age on 
pregabalin pharmacokinetics, although preliminary ﬁ  ndings 
suggest that the clearance of the drug decreases in elderly Neuropsychiatric Disease and Treatment 2008:4(6) 1213
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patients (May et al 2007), as anticipated because of the 
known reduction in renal function in old age (Perucca 2006). 
As expected, pregabalin clearance is reduced in patients with 
renal insufﬁ  ciency (Randinitis et al 2003). A 50% reduction 
in daily dose is recommended for patients with creatinine 
clearance between 30 and 60 mL/min, compared with doses 
used in patients with creatinine clearance 60 mL/min. 
Further dose reductions are indicated in the presence of more 
severe renal insufﬁ  ciency. Since pregabalin is removed exten-
sively by hemodialysis, supplemental doses may be required 
after a dialysis session (Randinitis et al 2003).
Drug interactions
Since pregabalin is eliminated virtually entirely by renal 
excretion and does not inﬂ  uence the activity of drug metabo-
lizing enzymes (Ben-Menachem 2004), clinically signiﬁ  cant 
pharmacokinetic drug-drug interactions are not expected to 
occur with pregabalin. Indeed, results of clinical studies are 
in agreement with this prediction. In particular, pregabalin 
does not appear to affect the plasma concentration of con-
comitantly administered carbamazepine, phenytoin, pheno-
barbital, valproic acid, gabapentin, lamotrigine, topiramate, 
oral contraceptives, oral hypoglycemics, diuretics and insulin 
(Ben-Menachem 2004; Brodie et al 2005; Janiczek-Dolphin 
et al 2005). Likewise, pregabalin pharmacokinetic does not 
appear to be affected by co-administration of other AEDs, 
although a recent study provided suggestive evidence that 
enzyme-inducing agents such as carbamazepine may cause 
a 20% to 30% reduction in plasma pregabalin concentrations 
at steady-state (May et al 2007).
Pregabalin has been shown to exert additive effects on the 
alterations in cognitive and gross motor functions caused by 
oxycodone, and to potentiate the central nervous system (CNS) 
effects of ethanol and lorazepam (Ben-Menachem 2004).
Clinical efﬁ  cacy against 
partial-onset seizures
Design of randomized controlled trials
Because it is considered unethical to treat active epilepsy in 
monotherapy with an agent whose clinical efﬁ  cacy is as yet 
unknown (Perucca 2008), new AEDs are initially evaluated 
as adjunctive therapy in patients whose seizures were not 
controlled by available treatments. These early trials are 
usually conducted in patients with partial-onset seizures, 
mainly because partial epilepsies represent the most prevalent 
refractory seizure disorder in an adult population.
Pregabalin was no exception to this rule, and to date 
randomized controlled trials with this agent have been largely 
conﬁ  ned to double-blind placebo-controlled studies in which 
the drug has been administered as adjunctive therapy to 
patients already receiving up to 3 concomitant AEDs. Overall, 
the patients enrolled in these trials were highly refractory in 
that they had a mean duration of epilepsy of 25 years and a 
median seizure frequency of 10 seizures per month, despite 
treatment over the years with a variety of AEDs (Brodie 2004; 
Elger et al 2005). Demonstrating efﬁ  cacy in such a refractory 
population may be regarded as a more challenging objective 
than performing a monotherapy study in a newly diagnosed 
population, because it requires achievement of additive 
seizure control in a population that is more likely to develop 
adverse drug effects due to presence of concomitant AEDs 
often administered at the highest tolerated dose.
Four randomized, double-blind, placebo-controlled 
parallel-group adjunctive-therapy trials of pregabalin have 
been completed in a total of 1396 patients with refractory 
partial-onset seizures, with or without secondary generaliza-
tion (French et al 2003; Arroyo et al 2004; Beydoun et al 
2005; Elger et al 2005; Brodie 2004; Ryvlin 2005; Warner 
and Figgit 2005; Lozsadi et al 2008) (Table 1).
In 3 fixed-dose studies, which enrolled a total of 
1052 patients, different dosing regimens were simultaneously 
evaluated (Table 1). All studies used a similar parallel-group 
design which involved an 8-week prospective baseline period 
followed by randomization to placebo and 2 to 4 different 
dosing regimens. Eligibility criteria for these studies included 
(i) a history of failure to obtain seizure control in spite of 
a trial of at least two AEDs at maximally tolerated doses; 
(ii) ongoing treatment with 1 to 3 AEDs; and (iii) occurrence 
of at least 6 partial seizures and no more than 4 weeks with-
out seizures during an 8-week baseline phase (French et al 
2003; Arroyo et al 2004; Beydoun et al 2005). In the ﬁ  rst 
study, which enrolled 453 patients aged 12 years and older 
in North America, patients were randomized to placebo 
or 50, 150, 300, or 600 mg/day pregabalin using a twice 
daily dosing regimen without titration (French et al 2003). 
The second study, conducted in Europe, South Africa and 
Australia, randomized 287 patients aged 18 years and older 
to placebo or pregabalin 150 or 600 mg/day with a 3 times 
daily dosing regimen with up to 1 week of titration (Arroyo 
et al 2004). In the third study, conducted in North America, 
312 patients (18 years old) were randomized to placebo, 
pregabalin 600 mg/day on a twice daily regimen or prega-
balin 600 mg/day on a 3 times daily regimen, each with up 
to 1 week of titration (Beydoun et al 2005).
Unlike the other trials, the fourth trial aimed at assessing 
the potential of pregabalin given with a ﬂ  exible dose regimen Neuropsychiatric Disease and Treatment 2008:4(6) 1214
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resembling routine clinical practice in comparison with a 
high-dose, ﬁ  xed-dose regimen (Elger et al 2005). In this 
12-week placebo-controlled trial, conducted at 53 centers 
in Europe and Canada, 341 patients aged 18 years and older 
were enrolled based on inclusion criteria that required con-
comitant treatment with up to 3 AEDs and occurrence of 
at least 4 partial-onset seizures with no more than 4 weeks 
without seizures during a 6-week baseline phase. Patients 
were then randomized to receive placebo, a ﬁ  xed pregabalin 
dose of 600 mg/day without titration or a ﬂ  exible pregaba-
lin regimen with dosages individually adjusted within the 
300 to 600 mg/day dose range (Table 1 and Figure 1). In the 
ﬂ  exible-dose group, pregabalin was started at 150 mg/day for 
2 weeks followed by 300 mg/day for the subsequent 2 weeks; 
thereafter, dosage could be increased to 450 mg/day for 
4 weeks and to 600 mg/day for another 4 weeks if a patient 
showed acceptable tolerability and was not seizure-free in 
each 4-week period. If intolerable adverse effects developed 
at 450 or 600 mg/day in the ﬂ  exible-dose group, dosage could 
be brought back to the previous level. In both groups, the 
total daily dose was given in two divided administrations. 
To maintain the blind, all patients could reduce the actual 
number of capsules of study medication, but only those in the 
ﬂ  exible-dose group received an actual drug reduction.
Table 1 Overview of randomized placebo-controlled double-blind trials of pregabalin in patients with refractory partial-onset seizures, 
with or without secondary generalization
Study Total pregabalin 
dose (mg/day)
Frequency of 
administrationa
Titration period Trial duration Number of 
patients (ITT)
French et al 2003 50 bid None 8 weeks baseline 453
150 bid 12 weeks double-blind
300 bid
600 bid
Arroyo et al 2004 150 tid 1 week 8 weeks baseline 287
600 tid 12 weeks double-blind
Beydoun et al 2005 600 bid 1 week 8 weeks baseline 312
600 tid 12 weeks double-blind
Elger et al 2005 Fixed 600 bid None 6 weeks baseline 341
Flexible 150–600 bid Flexible 12 weeks 12 weeks double-blind
abid, twice daily; tid, three times daily.
6-Week
Baseline
Period
Open-Label
Period
1–3 AEDs
12-Week 
Double-Blind
Period
Placebo 
150
300
450
600
600 mg/day fixed dose arm
150–600 mg/day dose 
adjustment phase
Week 0 Week 2 Week 4 Week 8 Week 12
6-Day tapering-off
or continuation of
open-label
pregabalin 
Figure 1 Trial design used in a pregabalin randomized ﬂ  exible-dose (150–600 mg/day) versus ﬁ  xed-dose (600 mg/day) double-blind adjunctive-therapy trial in patients with 
refractory partial-onset seizures, with or without secondary generalization. Adapted from Elger et al 2005.Neuropsychiatric Disease and Treatment 2008:4(6) 1215
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Efﬁ  cacy endpoints
Complete seizure freedom is the ultimate goal of antiepileptic 
treatment for both physicians and patients alike. However, 
since the typical patient populations recruited in adjunctive 
therapy trials of new AEDs are highly refractory, complete 
seizure control is not really a realistic expectation in these 
patients (Walker and Sander 1996). Thus, in common with 
other adjunctive therapy trials and as recommended by FDA 
and EMEA guidelines (Committee for Proprietary Medicinal 
Products 2000; French 2001; Mohanraj and Brodie 2003), 
the primary endpoints employed in the add-on pregabalin 
trials focused on changes in seizure frequency between the 
baseline period and the treatment period.
Traditionally, changes in seizure frequency are determined 
by counting seizures during the baseline and treatment period 
and then comparing the results (expressed in terms of frequency, 
eg, seizure counts per 28-day epoch) in patients receiving the drug 
with those obtained in patients receiving placebo. A problem with 
analyzing seizure frequency data, however, relates to the non-
normal distribution of the data and the high degree of variation 
both between subjects and within subjects (French 2001). In 
particular, while seizure frequency can only be reduced by a 
maximum of 100%, there is no limit to the percentage increase 
that this parameter can undergo. In the pregabalin trials, this 
problem has been resolved by using the Response Ratio (RRatio) 
as the primary measure of seizure reduction. The RRatio is 
deﬁ  ned as the difference between the 28-day seizure rates dur-
ing treatment (T) and during baseline (B), divided by the sum of 
baseline and treatment seizure rates, and multiplied by 100:
RRatio =
−
+
×
TB
TB
100
The advantage of the RRatio is that all values fall within 
the range between –100 and +100, and can be analyzed using 
parametric statistical methods (Mohanraj and Brodie 2003). 
Negative values of the RRatio represent an improvement in 
seizure rate (for example, a value of –33 is equivalent to a 
50% reduction in seizure frequency versus baseline), whereas 
positive values reﬂ  ect a deterioration. The percent change 
in seizure frequency from baseline can be derived from the 
RRatio by using the following formula (Arroyo et al 2004):
Percent change in seizure rate from baseline
=
(200 RRatio)
(
×
1 100 RRatio) -
Since percent change in seizure frequency reﬂ  ects more 
directly the magnitude of response and is a more familiar 
measure to physicians, in the current review efﬁ  cacy results 
have been converted to this parameter. Additionally, as 
required by EMEA guidelines (Committee for Proprietary 
Medicinal Products 2000), efﬁ  cacy data were also expressed 
by categorizing patients into responders and non-responders, 
with responders being conventionally defined as those 
patients who had a reduction in seizure frequency by at least 
50% compared with baseline.
Experience with previous drug trials in epilepsy has 
shown that only few drug-refractory patients achieve seizure 
freedom after starting adjunctive-therapy with a new AED. 
Therefore, seizure freedom is unsuitable for use as a primary 
endpoint, although it may be assessed as a secondary end-
point. As discussed in detail in a recent publication (Leppik 
et al 2006), there are different ways to deﬁ  ne freedom from 
seizures. One aspect of the deﬁ  nition relates to the minimum 
length of time without seizure that is required to categorize a 
patient as seizure-free. In the pregabalin trials, the last 28 days 
of double-blind treatment was selected as the period during 
which freedom from seizures was evaluated, a choice justiﬁ  ed 
by the high median seizure frequency of the enrolled patients 
(about 10 seizures per month) and the requirement that no 
patient could have a 28-day seizure-free interval during the 
baseline. There is also scope in assessing the proportion of 
patients free from seizures during the entire double-blind 
treatment period, which is likely to be a more clinically 
meaningful measure. However, choice of this endpoint 
raises the question of how patients who discontinued the 
study early during treatment should be evaluated, and which 
patients should be included in the analysis. For example, if a 
patient discontinued treatment after 7 days because of adverse 
effects and had no seizure during that brief period, should 
that patient be counted as seizure-free in the calculation of 
seizure-free rates? In the conventional intent-to-treat (ITT) 
analysis, responses during the available observation period 
are extrapolated to the entire treatment period (the so-called 
last-observation-carried-forward analysis), and therefore any 
patient discontinuing treatment prematurely prior to occur-
rence of any seizure would be regarded as seizure-free. It 
is clear, however, that this method of calculation leads to 
overestimation of actual seizure-free rates, particularly in 
groups randomized to doses which are associated with high 
discontinuation rates. A conservative approach that avoids 
this problem is to consider as seizure free only those patients 
who complete the entire treatment period without seizure, 
and calculating seizure-free rates by using the entire ITT 
population as denominator (Leppik et al 2006). A comparison 
of seizure freedom rates in ﬁ  xed-dose pregabalin rates using Neuropsychiatric Disease and Treatment 2008:4(6) 1216
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these two methods (eg, last-observation-carried-forward 
ITT analysis versus ITT analysis in which only seizure-free 
completers are considered) has been conducted (Gazzola 
et al 2007). Additionally, an intermediate approach has also 
been used, in which an ITT last-observation-carried-forward 
analysis was performed but only patients who had been on 
medication for at least 28 days and completed at least 75% 
of their seizure diary could be considered seizure-free.
Another type of seizure freedom analysis used in AED 
trials involves counting the number of seizure-free days in 
each treatment group (French and Arrigo 2005). This type of 
analysis considers each day individually for each patient and 
examines whether or not a seizure has occurred: proportion of 
patients free from seizures on any treatment day can then be 
compared across treatment groups. This approach, which has 
the advantage of providing information on speed of onset of 
anticonvulsant activity and potential changes in magnitude of 
response over time, was used in a post-hoc analysis of pooled 
data from ﬁ  xed-dose pregabalin trials (Perucca et al 2002).
Efﬁ  cacy results from ﬁ  xed-dose trials
The three ﬁ  xed-dose placebo-controlled studies provide valu-
able information for the characterization of dose-response 
relationships, including identiﬁ  cation of a minimum effective 
dose and of a maximal tolerated dose, and exploration of 
optimal dosing intervals. In each of these studies, pregabalin, 
given either 2 or 3 times daily, exhibited clear efﬁ  cacy in 
reducing seizure frequency when administered as adjunc-
tive therapy in patients with refractory partial-onset seizures 
(French et al 2003; Arroyo et al 2004; Beydoun et al 2005).
At baseline, patients had a mean seizure rate of 24.4 
seizures per month (median 11.2 per month), and 73% 
were receiving a combination of least 2 AEDs (Brodie 
2004; Ryvlin 2005). RRatios and corresponding percent 
reductions in seizure frequency as a function of the allo-
cated dose in each of the three trials are shown in Figure 2. 
Seizure frequency was signiﬁ  cantly reduced, in comparison 
to placebo, at doses of 150, 300 and 600 mg/day, whereas 
response at the 50 mg/day dose did not differ signiﬁ  cantly 
from placebo (French et al 2003; Brodie 2004; Ryvlin 2005). 
The minimal effective dose was therefore established at 
150 mg/day. The decrease in seizure frequency over the 
assessed dose range was also found to be dose-dependent, 
irrespective of the dosing regimen used (twice or three times 
daily). Responder rates (proportion of patients with 50% 
reduction in seizure frequency compared with baseline) also 
increased with increasing dose, and ranged from 14% to 51% 
in pregabalin groups compared to 6% to 14% in the placebo 
groups (Figure 3).
A recent additional post-hoc analysis of pooled data 
from the three ﬁ  xed-dose trials examined the inﬂ  uence of 
pregabalin on secondarily generalized tonic-clonic seizures 
(Briggs et al 2008). In this analysis, a 600 mg/day dose was 
found to be signiﬁ  cantly superior to placebo in reducing the 
absolute frequency of secondarily generalized tonic-clonic 
seizures, but the effect appeared to be related to suppression 
of partial-onset seizures rather than to inhibition of secondary 
generalization.
Across the ﬁ  xed-dose trials, between 3% and 17% of 
patients randomized to effective doses were seizure-free 
Pregabalin Dose (mg/day)
(Placebo)
French et al 2003 (bid)   Beydoun et al 2005 (bid)  
Beydoun et al 2005 (tid)  
p = 0.0007  
p ≤ 0.0001   Arroyo et al 2004 (tid)  
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Figure 2 Seizure reduction in short-term ﬁ  xed-dose pregabalin adjunctive therapy studies. Dose response relationship for seizure reduction (shown as response ratio [RRatio] 
on right y axis and percent change from baseline as calculated from RRatio on left y-axis) is shown for each of the three short-term ﬁ  xed-dose pregabalin studies (French et al 
2000; Arroyo et al 2004; Beydoun et al 2005). P values shown represent a signiﬁ  cant difference from placebo in the same study. Adapted from Brodie et al 2004.Neuropsychiatric Disease and Treatment 2008:4(6) 1217
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during the last 28 days of treatment, and seizure-free rates 
increased with increasing doses (Brodie 2004). In comparison, 
no more than 1% of patients allocated to the placebo groups 
were free from seizures during the corresponding period. 
In the ITT last-observation-carried-forward analysis of all 
patients randomized to pregabalin in each trial (all doses), 
seizure-free rates across the entire treatment period ranged 
across trials from 3.7% to 7.9% (Gazzola et al 2007). 
However, in the conservative ITT analysis in which only 
completers could be considered seizure-free (ie, patients 
withdrawing from the trial were considered not seizure-
free, even when no seizures had occurred up to the time of 
withdrawal), seizure freedom rates decreased to 1.3% to 
1.4% (Gazzola et al 2007). In the modiﬁ  ed ITT analysis in 
which the last-observation-carried-forward extrapolation 
was applied only to patients who had been on medication 
for at least 28 days and had completed at least 75% of their 
seizure diary, signiﬁ  cantly higher seizure-free rates on pre-
gabalin than on placebo were found for the 300 mg/day dose 
(1 study – French et al 2003) and for the 600 mg/day dose 
(3 studies – French et al 2003; Arroyo et al 2004; Beydoun 
et al 2005).
Seizure-free days analysis on the pooled dataset including 
ﬁ  ve doses (150–600 mg/day) in ﬁ  xed-dose studies showed 
that the onset of pregabalin action is rapid, with a reduction 
in seizure activity compared with placebo being already 
statistically significant on the second day of treatment 
(Perucca et al 2002). The reduction in seizure activity 
documented by seizure-free day analysis persisted throughout 
the 12-week evaluation period.
In conclusion, the ﬁ  xed-dose studies have shown that 
adjunctive therapy with pregabalin is effective in reducing 
dose-dependently the frequency of partial-onset seizures 
within the 150 to 600 mg/day dose range. Efﬁ  cacy was 
comparable with either twice or three times daily dosing, 
was rapid in onset and persisted for the full duration of 
assessment. These ﬁ  ndings provide the rationale for the 
implementation of a monotherapy development programme, 
which is underway.
Efﬁ  cacy results from the ﬂ  exible-dose trial
The efﬁ  cacy of pregabalin in reducing the frequency of 
partial-onset seizures was conﬁ  rmed in the trial that compared 
ﬁ  xed (600 mg/day) with ﬂ  exible dosing (150–600 mg/day) 
(Elger et al 2005). The percent reduction in the frequency 
of seizures was statistically signiﬁ  cant (p  0.01) both 
in the group allocated to a ﬁ  xed dose (49.3%) and in the 
group allocated to a ﬂ  exible dose (35.4%), compared with 
the group allocated to placebo (10.6%). Proportions of 
patients with a 50% seizure reduction were 45.3% in the 
ﬁ  xed-dose group (p  0.001 versus placebo) and 31.3% in 
the ﬂ  exible-dose group (p  0.001), compared with 11.0% 
in the placebo group. These rates are comparable to those 
found in the ﬁ  xed-dose trials (Figure 3). Seizure freedom 
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rates during the last 28 days of treatment were 12.4% in the 
ﬁ  xed-dose group, 12.2% in the ﬂ  exible-dose group, and 8.2% 
in the placebo group.
Comparison with results
from randomized controlled trials 
with other second generation AEDs
Responder rates with pregabalin in adjunctive-therapy 
randomized controlled trials compare favorably with 
those reported in similarly designed trials of other second 
generation AEDs in patients with refractory partial-onset 
seizures (Cramer et al 1999; Brodie 2004). However, 
when comparing data from different trials, differences in 
responder rates in the groups assigned to placebo should also 
be considered. Therefore, rather than comparing absolute 
responder rates, it may be more relevant to compare the 
relative risk (RR) of being a responder on drug treatment 
in relation to the responder rate on placebo. Indirect 
comparisons should also take into account systematic bias 
such as the differences in placebo response rates between 
pediatric and adult populations (Rheims et al 2008). In a 
systematic review of all randomized controlled AED trials 
in adults with refractory partial epilepsy, in which the above 
confounders were taken into account, pregabalin ranked 
second in efﬁ  cacy among the 10 most recently developed 
AEDs (Ryvlin et al 2006). When ineffective dosages were 
excluded from the analysis, pregabalin was associated 
with the highest RR for 50% responder rates, followed 
in decreasing order of responder rates by levetiracetam, 
topiramate, oxcarbazepine, tiagabine, zonisamide, vigabatrin, 
gabapentin, and lamotrigine (Ryvlin et al 2006). However, 
95% conﬁ  dence intervals of RRs overlapped for all the 
assessed drugs, indicating that differences among AEDs 
failed to reach statistical signiﬁ  cance. This is more likely to 
reﬂ  ect the low statistical power of the comparisons, rather 
than equivalence of responder rates among AEDs.
Long-term efﬁ  cacy data
Most patients with epilepsy need to continue treatment for 
many years, sometimes for a lifetime. Therefore, it is impera-
tive that the long-term efﬁ  cacy and safety of any new AEDs 
be carefully investigated. Since it would be unethical to keep 
patients who are prone to seizures on placebo treatment for sev-
eral years under double-blind conditions for comparative pur-
poses, data on long-term efﬁ  cacy and safety must be obtained 
in open-label follow-up studies. It is usual for these studies to 
be an extension of placebo-controlled trials, and this was also 
the case for most follow-up studies with pregabalin.
In clinical studies with a follow-up of several years, 
seizure freedom is probably the most useful indication of a 
drug’s efﬁ  cacy, since this is the ultimate goal of AED treat-
ment (Mohanraj and Brodie 2003). The most meaningful 
seizure freedom measure under these conditions is probably 
represented by the proportion of patients who are free from 
seizures over a pre-deﬁ  ned period. Additional outcome 
measures that may be used to evaluate clinical beneﬁ  t over 
time include the number of seizure-free days over different 
intervals, and the proportion of responders (patients with 
a reduction in seizure frequency by 50% compared with 
pre-treatment) at different time points during follow-up. 
Whatever outcome measure is selected, results need to be 
interpreted cautiously not only because of the uncontrolled 
nature of these observations, but also because of confounders 
such as concomitant changes in underlying AED treatment, 
difﬁ  culties with accounting for patients who discontinue the 
study drug (resulting in an “enriched population”, whereby 
only those patients who appear to beneﬁ  t from the drug 
remain on it), and the potential bias caused by missing data 
from patients lost to follow-up.
In the case of pregabalin, an assessment of long-term 
outcome has been made based on results in 4 open-label 
studies in a total of 1480 patients, representing a cumulative 
exposure of 3150 patient-years (Pﬁ  zer, data on ﬁ  le). Of these 
patients, 968 took part in earlier randomized double-blind 
trials or in a small short-term in-patient monotherapy 
trial, while 512 started open-label treatment de novo. 
Follow-up of this population has been complicated by the 
fact that about 2 to 3.5 years after enrolment, the Food 
and Drug Administration (FDA) stipulated that patients 
in the United States could remain in these studies only 
if they were refractory to other AEDs and had shown a 
favorable response to pregabalin, defined as a reduction 
by at least 30% in the frequency of their seizures relative 
to pre-treatment.
At the time of completion of the open-label studies, 
approximately 20% of patients had received pregabalin 
for 5 years, 35% for 2 years, 59% for 1 year and 
77% for 24 weeks. Overall, 71% and 48% of patient 
years were exposed to pregabalin doses 450 mg/day and 
600 mg/day, respectively. At the time of enrolment in the 
open-label period, about 50% of the patients were receiv-
ing two concomitant AEDs. The FDA requaliﬁ  cation of 
the criteria for remaining in the study led to withdrawal of 
188 patients (13% of those initially enrolled, and 44% of the 
431 patients that were assessed for requaliﬁ  cation). Since 
the requaliﬁ  cation process complicates the interpretation of Neuropsychiatric Disease and Treatment 2008:4(6) 1219
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long-term outcome by allowing continuation in the study 
only for patients who were responding favorably, the data 
collected after the time of initial requaliﬁ  cation were not 
included in the analysis of changes in seizure frequency. 
Assessment of seizure freedom data, however, was done 
also done on all data.
After exclusion of data collected after requaliﬁ  cation, 
the mean number of seizure-free days per 28-day period 
increased from 18.3 days at pre-treatment to 21.6 days 
during pregabalin treatment, with an overall mean 39% 
increase in seizure-free days in individual patients. Of 
892 patients with a follow-up of at least 6 months prior to 
requaliﬁ  cation, 69 (7.7%) were seizure-free during their 
last 6 months on pregabalin treatment, whereas of 710 
patients with a follow-up of at least 1 year, 26 (3.7%) were 
seizure-free during the last 12 months (Table 2). When the 
same analysis was done on all ITT data (including those 
collected after requaliﬁ  cation), the mean number of sei-
zure-free days per 28-day period increased from 18.3 days 
at pre-treatment to 21.5 days during pregabalin treatment, 
with a mean 41.6% increase in number of seizure-free 
days in individual patients. In this enlarged analysis, the 
proportions of patients seizure-free during the last 6 and 
12 months of treatment were 9.2% (103/1119) and 8.1% 
(71/877), respectively (Table 2).
In the subgroup of evaluable patients who had partici-
pated in ﬁ  xed-dose double-blind trials, assessment of seizure 
frequency during the ﬁ  rst 12 weeks of open-label treatment 
indicated that 37% had a seizure-reduction of at least 50% 
compared with baseline. For those patients who had remained 
in the study for 2 years, the responder rate during the initial 
12-week open-label period was 52% and remained in the 
range of 50% to 58% during subsequent intervals. For 
the cohorts of patients that had remained in the study for 
6 months or 1 year, a similar pattern of sustained reduction 
in seizure frequency compared with baseline was observed. 
These data suggest that response to pregabalin is maintained 
during long-term treatment, although, as discussed above, 
interpretation should be cautious because an inﬂ  uence of 
several potential bias cannot be excluded in open-label long-
term follow-up studies.
Safety and tolerability proﬁ  le
Results from randomized-controlled trials
A useful assessment of adverse effects associated with 
pregabalin treatment and their relationship to dose in patients 
with refractory partial-onset seizures can be derived from the 
four double-blind adjunctive-therapy studies conducted in 
this population (French et al 2003; Arroyo et al 2004; Brodie 
2004; Beydoun et al 2005; Elger et al 2005; Ryvlin 2005; 
Warner and Figgitt 2005). Table 3 lists the most common 
adverse events in patients allocated to each pregabalin dose 
group and to placebo in a pooled analysis of these trials 
(French et al 2003; Arroyo et al 2004; Beydoun et al 2005; 
Elger et al 2005).
In ﬁ  xed-dose trials, dizziness was the most frequently 
reported adverse event and showed a clear relationship with 
dose, being recorded in about one third of patients at 300 and 
600 mg/day, compared with one tenth of patients allocated to 
placebo. Somnolence, ataxia and fatigue also increased in fre-
quency with increasing doses, whereas headache occurred in 
all dose groups at a frequency comparable with that recorded 
Table 2 Seizure freedom rates in patients treated with long-term adjunctive-therapy pregabalin
Elapsed time 
between last 
seizure and ﬁ  nal 
observation
All patients, all data Data up to initial requaliﬁ  cationa
Number 
assessed
Number 
seizure-free
% seizure-
free
Number 
assessed
Number 
seizure-free
% seizure-
free
At least 1 month 1423 311 21.9% 1115 219 19.6%
At least 2 months 1361 203 14.9% 1064 145 13.6%
At least 3 months 1300 156 12.0% 1018 105 10.3%
At least 4 months 1250 128 10.2% 984 83 8.4%
At least 6 months 1119 103 9.2% 892 69 7.7%
At least 1 year 877 71 8.1% 710 26 3.7%
At least 2 years 511 42 8.2% 192 6 3.1%
At least 3 years 354 26 7.3% 59 1 1.7%
Notes: Results are pooled data from four open-label studies using both the entire ITT population (all data) and the ITT population with only data obtained before a patient’s 
initial requaliﬁ  cation.
aPatients from the US were required to undergo requaliﬁ  cation to determine eligibility to continue in the trial, and only data collected prior to initial requaliﬁ  cation were 
included for these patients (see text). For unaffected patients, data for the entire open-label treatment period were included.Neuropsychiatric Disease and Treatment 2008:4(6) 1220
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in patients randomized to placebo. Adverse events were 
generally mild to moderate, they tended to occur mostly in 
the ﬁ  rst 2 weeks of treatment, and they often resolved without 
adjustment in dose. Serious treatment-related adverse events 
occurred in 4 cases among pregabalin-treated patients and 
in 2 cases treated with placebo (Brodie 2004). In ﬁ  xed-dose 
studies, 15% of patients allocated to pregabalin discontinued 
treatment prematurely because of adverse events, compared 
with 6% of patients allocated to placebo (Brodie 2004; 
Ryvlin 2005). At 50 and 150 mg/day, discontinuation rates 
were comparable to those recorded in the placebo group, 
whereas at higher doses discontinuation rates increased 
dose-dependently. At the highest dose of 600 mg/day, 24% of 
patients withdrew prematurely for adverse events (Table 3).
The possible relationship between adverse events and 
dosing frequency was assessed in a double-blind trial in 
which groups were randomized to the same total daily dose 
(600 mg/day) given in either 2 or 3 divided daily administra-
tions (Beydoun et al 2005). There was no clear evidence of 
either dosing regimen being superior to the other in terms 
of efﬁ  cacy or tolerability. The most common adverse event, 
dizziness, occurred in 41.7% of patients allocated to the 
twice daily regimen and in 37.8% of those allocated to the 3 
times daily regimen. Somnolence was slightly more common 
in the twice daily group than in the three times daily group 
(30.1% vs 23.4%). Discontinuation rates for adverse events 
were also slightly higher with the twice daily regimen than 
in the 3 times daily regimen (26% vs 19%, respectively), 
suggesting that some patients may tolerate the latter regimen 
more favorably.
In the ﬂ  exible-dose study, gradual up-titration of dose, 
associated with dose reduction if intolerable adverse events 
occurred, was found to have a clearly favorable impact on 
pregabalin’s tolerability (Elger et al 2005). In this study, 
dizziness was the most common adverse event in both 
groups, but it occurred with a much lower frequency in 
patients allocated to flexible-dosing (150–600 mg/day) 
than in those allocated to 600 mg/day ﬁ  xed-dose without 
titration (24.4% vs 43.1%, respectively). Ataxia and weight 
gain were the other most commonly reported adverse events 
in the ﬁ  xed-dose group, and occurred in 21.2% and 20.4% 
of patients, respectively. Other adverse events in the ﬂ  ex-
ible-dose group included somnolence and weight gain, each 
occurring in 19.1% of patients. The overall improvement 
in tolerability in the group allocated to ﬂ  exible-dosing was 
best reﬂ  ected by the ﬁ  nding that only 12.2% of patients in 
this group discontinued treatment because of adverse events, 
a proportion only slightly higher than that reported in the 
group allocated to placebo (6.8%). Conversely, about one 
third of patients (32.8%) allocated to the ﬁ  xed-dose group 
withdrew because of adverse events. As shown in Figure 4, 
discontinuation of treatment, which was mostly caused by 
adverse events, occurred mostly during the ﬁ  rst weeks of 
treatment, particularly in the ﬁ  xed-dose group. In the ﬁ  rst 
week of treatment, only 3% of patients in the ﬂ  exible dose 
group withdrew due to adverse events, compared with 24% of 
those allocated to the ﬁ  xed-dose group. In summary, the data 
indicate that pregabalin tolerability is improved by gradual 
titration from a starting dose of 150 mg/day, with subsequent 
adjustment according to clinical response. It is reasonable 
Table 3 Most common adverse events reported in randomized placebo-controlled double-blind trials of pregabalin in patients with 
refractory partial-onset seizures, with or without secondary generalization
Adverse event
Frequency (%)
Pregabalin daily dose
50 mg 150 mg 300 mg 600 mg Flexible, 
150–600 mg
Placebo
n = 88 n = 187 n = 90 n = 533 n = 131 n = 294
Dizziness 9.1 17.6 31.1 33.8 24.4 10.5
Somnolence 10.2 11.2 17.8 25.5 19.1 10.9
Ataxia 3.4 5.9 10 19.9 9.2 4.1
Fatigue 5.7 10.7 12.2 18 16.8 8.2
Headache 6.7 7.5 5.6 10.1 13.7 11.6
Weight gaina 1.1 4.8 6.7 17.1 19.1 1.4
Withdrawal for adverse events 6.9 5.9 14.4 24.2 12.2 6.3
Notes: Data were pooled from four studies (French et al 2003; Arroyo et al 2004; Beydoun et al 2005; Elger et al 2005). Some patients reported 1 adverse event.
aWeight gain spontaneously reported as an adverse event by patient.Neuropsychiatric Disease and Treatment 2008:4(6) 1221
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to expect that, in most situations, such a ﬂ  exible regimen 
will reﬂ  ect the optimal mode of use of the drug. However, 
the fact that the majority of patients in the ﬁ  xed-dose group 
tolerated the maximum dose (600 mg/day) from the outset 
indicates that initiation with high doses without titration is 
a feasible option, particularly in special cases where rapid 
attainment of seizure control is an utmost priority.
An adverse event that appears to be unrelated to speed 
of titration is an increase in body weight. Overall, in double-
blind studies, weight gain was spontaneously reported as an 
adverse event in 10.4% of pregabalin-treated patients com-
pared with 1.4% of patients treated with placebo. However, 
only 0.4% of patients in double-blind studies discontinued 
treatment as a result of weight gain. In ﬁ  xed-dose trials, the 
proportion of patients reporting increased body weight as an 
adverse event increased with increasing dose, from 1.1% at 
50 mg/day to 4.8% at 150 mg/day, 6.7% at 300 mg/day and 
17.1% at 600 mg/day (Table 3). In all double-blind trials, 
body weight was measured at baseline and at the last study 
visit. By deﬁ  ning as signiﬁ  cant an increase by 7% over 
baseline, a signiﬁ  cant gain in weight was observed in 18% 
of pregabalin-treated patients, compared with 2.1% of those 
treated with placebo. In the majority of these patients, the 
weight increase did not exceed 10% of the baseline weight. 
Change in weight were not associated with changes in lipids 
or loss of glycemic control.
No deaths were recorded during pregabalin double-blind 
epilepsy trials. In trials conducted in other indications, the 
tolerability proﬁ  le of pregabalin was similar to that reported 
in patients with epilepsy, except for peripheral oedema which 
occurred more commonly in studies conducted in neuropathic 
pain than in epilepsy trials (Freeman et al 2008). Pregabalin 
has been designated as a Schedule V controlled substance in 
the United States because of concerns about possible abuse and 
dependence. These concerns, however, do not appear to be of 
signiﬁ  cance for the use of pregabalin as an antiepileptic drug.
Results from long-term follow-up studies
Adjunctive-therapy with pregabalin was in general relatively 
well tolerated in long-term open-label studies, and no new safety 
concerns have been identiﬁ  ed during extended follow-up. Of 
1480 patients included in the four open-label studies discussed 
above, 23 died during or after the studies for reasons that the 
investigator did not consider related to the drug. In 5 cases of 
these cases, death appeared to be related to seizures (Pﬁ  zer, data 
on ﬁ  le). There were 246 patients with serious adverse events, 
but in only 15 cases (1.0% of the total population) were these 
considered to be related to pregabalin. Overall, 193 patients 
(13%) withdrew due to adverse events, which were considered 
as treatment-related in 160 (11%) patients.
Most adverse events during long-term studies were 
comparable to those that emerged in randomized controlled 
studies. Adverse events recorded during long-term treatment 
in 5% of patients included dizziness, somnolence, weight 
gain, ataxia, visual disturbances, difﬁ  culties with attention/
concentration, nausea, tremor, amnesia, depression, insomnia, 
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Figure 4 Kaplan-Meier analysis of time to discontinuation due to adverse events with ﬂ  exible (150–600 mg/day) versus ﬁ  xed (600 mg/day) pregabalin dosing. Patients in the 
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nervousness, anxiety, and confusion. Most of these events 
were mild or moderate in intensity and often resolved with 
continued treatment. Accidental injury, infection, headache, 
asthenia, and pain were also recorded in an appreciable 
proportion of patients (Table 4), but they were generally not 
considered to be drug-related. Infrequently reported adverse 
events include myoclonus (Huppertz et al 2001; Hellwig 
et al 2008; Kalviainen et al 2008; Modur and Milteer 2008), 
painful gynecomastia (Málaga and Sanmarti 2006), and erec-
tile dysfunction (Hitiris et al 2006). Very rarely did adverse 
events lead to discontinuation of treatment (Table 4).
The proportion of patients reporting weight gain as an adverse 
event was 24%. The mean weight gain at study termination 
compared with baseline was approximately 5 kg, with 44% 
of patients gaining 7% of their initial weight. In contrast to 
short-term trials which suggested a relationship between weight 
gain and pregabalin dose, in long-term studies weight gain did 
not appear to correlate with absolute dose (mg/day), weight-
normalized dose (mg/kg/day), or categorized dosage (more or 
less than 300 mg/day) (Hoppe et al 2008). In one study, extended 
patient counseling was not found to be effective in preventing 
the occurrence of weight gain (Hoppe et al 2008).
Conclusions
Although the pregabalin clinical trial program was primarily 
designed to provide proof of efﬁ  cacy and safety for regulatory 
purposes, the ﬁ  ndings also provide relevant information 
for the practicing physician. Four randomized-placebo-
controlled studies have demonstrated that pregabalin is 
effective as adjunctive therapy in the management of adults 
with partial-onset seizures, with or without secondary gen-
eralization (Ryvlin et al 2006; Beydoiun et al 2008; Lozsadi 
et al 2008). Since pregabalin in these studies did not affect 
the plasma levels of concomitantly administered drugs, its 
efﬁ  cacy cannot be explained by pharmacokinetic interactions 
with underlying AEDs.
In short-term trials, pregabalin reduced seizure frequency 
signiﬁ  cantly at doses between 150 and 600 mg/day, with a 
clear dose-response relationship and a rapid onset of action. 
Efﬁ  cacy appeared to be maintained during long-term treat-
ment, with no clear evidence of tolerance developing over 
a follow-up period of up to 4 years. In long-term open-label 
studies, close to 8% of pregabalin-treated patients were free 
from seizures during the last 6 months of observation, and 
3.7% were seizure-free during the previous 12 months.
In ﬁ  xed-dose studies, dizziness and sedation were the 
most common dose-limiting adverse events. Up to a dosage 
of 300 mg/day, discontinuation rates for adverse events 
were similar or only slightly higher than those reported in 
placebo-treated patients, but at a dosage of 600 mg/day a 
quarter of patients withdrew prematurely due to adverse 
events. Although most patients can tolerate doses as high as 
600 mg/day without titration, tolerability is clearly improved 
by gradual dose titration and dose adjustments according to 
clinical response (Elger et al 2005). A twice daily dosing 
regimen appears to be generally appropriate, although a 
3 times daily regimen may be considered if treatment is 
suboptimally tolerated, particularly in patients receiving 
doses in the upper range.
Based on available data, adjunctive pregabalin will be 
a useful therapeutic tool for clinicians concerned with the 
long-term management of patients with refractory partial 
epilepsy. Given the efﬁ  cacy of pregabalin in the treatment of 
generalized anxiety disorder and neuropathic pain, patients 
with these comorbidities appear to be particularly suitable 
candidates to pregabalin treatment. Pregabalin has not been 
found to be useful in generalized epilepsies, and may even 
aggravate seizures when used in patients with certain gen-
eralized epilepsy syndromes such as progressive myoclonic 
epilepsies (Kalviainen et al 2008). Among patients with 
partial epilepsy, no speciﬁ  c factors have been identiﬁ  ed that 
may be used to predict responsiveness to pregabalin. In most 
cases, an already effective starting dose can be 150 mg/day, 
given in 2 divided administrations, without the need for 
Table 4 Most common adverse events (reported by 10% of all 
patients) among 1480 patients treated with long-term adjunctive-
therapy pregabalin based on pooled data from 4 open-label 
studies
Adverse event Frequency (%) Withdrawals 
due to event (%)
Dizziness 33.9 1.4
Accidental injury 28.6 0.3
Somnolence 27.4 1.7
Weight gaina 23.6 2.0
Infection 22.4 0
Headache 20.0 0.6
Asthenia 19.9 1.2
Pain 17.8 0.1
Ataxia 14.3 0.8
Amblyopia 14.1 0.5
Diplopia 11.8 0.2
Thinking abnormalb 11.7 0.9
Nausea 10.5 0.6
aWeight gain spontaneously reported as an adverse event by patient.
bCoded term used to indicate difﬁ  culties with attention or concentration.Neuropsychiatric Disease and Treatment 2008:4(6) 1223
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titration. If needed for additional efﬁ  cacy, doses of 300 and 
600 mg/day may be used, and increasing dose ﬂ  exibly in 
relation to efﬁ  cacy and tolerability appears to be the best 
strategy to ensure an optimal clinical response.
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